Elagolix Treatment in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids: Efficacy and Safety Results From a Phase 2B Study

Study Objective: To evaluate safety and efficacy of elagolix, an oral, non-peptide, gonadotropin-releasing hormone antagonist, with/without add-back therapy in women with heavy menstrual bleeding (HMB) associated with uterine fibroids (UF).